Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

D-galactosamine based canine acute liver failure model.

John F Patzer1, Geoffrey D Block, Ajai Khanna

  • 1Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261, USA. patzer@pitt.edu

Hepatobiliary & Pancreatic Diseases International : HBPD INT
|November 11, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity.

bioRxiv : the preprint server for biology·2026
Same author

AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Candidate evaluation.

Hepatology (Baltimore, Md.)·2026
Same author

Portal Vein Thrombosis in Pediatric Liver Transplantation With Technical Variant Grafts: An International Multicenter Analysis of Risk and Prognostic Factors.

Transplantation·2026
Same author

A remote intervention to improve medication nonadherence guided by a marker of risk derived from the electronic health records of adolescent transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Strategies and Innovations Defining the Next Era in Pediatric Liver Transplantation: Unifying Concepts to Tackle a Rare Disease.

Pediatric transplantation·2026
Same author

Minimal Clinically Important Difference for the PeLTQL in Pediatric Liver Transplantation: A Multicenter Analysis.

Pediatric transplantation·2026

This study introduces a new canine model for acute liver failure induced by the chemical D-galactosamine. The researchers designed this model to better mimic human liver failure symptoms, providing a reliable platform for testing bioartificial liver support systems. By monitoring physiological markers and neurological status, the team successfully replicated severe liver damage and associated complications, such as intracranial pressure changes. This model offers a standardized approach for evaluating future liver-assist technologies.

Area of Science:

  • Veterinary medicine and D-galactosamine hepatotoxicity research
  • Bioartificial liver device development within clinical hepatology

Background:

No prior work had resolved the need for a large animal model that accurately replicates human acute liver failure for testing bioartificial liver devices. Previous canine models often introduced experimental artifacts that limited their clinical utility. Researchers required a more precise platform to evaluate the safety and efficacy of liver support systems. This gap motivated the development of a refined canine model using specific chemical induction. The current study addresses these limitations by providing a standardized, lethal model of hepatic failure. Investigators aimed to improve upon earlier methodologies that failed to capture essential clinical features. This model allows for rigorous monitoring of physiological parameters during the progression of liver disease. Such advancements are necessary for the successful translation of liver-assist technologies into human clinical practice.

Purpose Of The Study:

The aim of this study is to present a refined canine model of acute liver failure suitable for evaluating bioartificial liver assist devices. Researchers sought to create a large animal platform that replicates the clinical features of human hepatic failure. The team intended to minimize experimental artifacts that plagued earlier models used in this field. By establishing a standardized induction protocol, they hoped to provide a reliable tool for preclinical testing. This work addresses the need for accurate qualitative and quantitative assessments of liver support systems. The investigators focused on monitoring physiological parameters to ensure the model reflects real-world clinical conditions. They aimed to provide a reproducible method for studying the progression of severe liver disease. This effort supports the advancement of therapeutic interventions for patients suffering from acute hepatic collapse.

Keywords:
hepatic failurecanine modelbioartificial liverpreclinical evaluation

Frequently Asked Questions

The researchers induced failure by administering 1.5 g/kg of D-galactosamine intravenously to male hounds. This chemical agent causes massive hepatic necrosis, leading to a lethal condition that mimics human acute liver failure symptoms, including coagulopathy and elevated intracranial pressure.

The study utilized a comprehensive monitoring suite, including arterial pressure, central venous pressure, pulmonary artery pressure, and extradural intracranial pressure sensors. These tools allowed the team to track physiological deterioration and manage the animals until they reached a defined death-equivalent state.

Invasive monitoring of intracranial pressure was necessary because the researchers found that all animals were refractory to maintaining cerebral perfusion pressure. This measurement allowed the team to correlate neurological obtundation with pressure elevations exceeding 50 mmHg in some subjects.

Related Experiment Videos

Main Methods:

Review approach involved utilizing six male hounds weighing between 24 and 30 kilograms for the experimental procedure. The team administered the chemical agent while the subjects were under isoflurane anesthesia to ensure humane handling. Supportive care protocols followed strict guidelines based on continuous invasive monitoring of various pressure systems. Researchers tracked arterial, central venous, pulmonary artery, and extradural intracranial pressures throughout the study duration. They also recorded end-tidal carbon dioxide levels to maintain physiological stability during the progression of hepatic damage. The team defined the terminal endpoint as a death-equivalent state based on specific hemodynamic criteria. This involved assessing the ability to sustain systolic blood pressure despite maximal fluid resuscitation and dopamine support. The investigators performed post-mortem histological analysis of liver tissue to confirm the extent of hepatic necrosis.

Main Results:

Key findings from the literature demonstrate that the mean survival time for the canine subjects was 43.7 plus or minus 4.6 hours. All animals exhibited significant increases in liver enzymes, with aspartate transaminase reaching 5977 IU/L and alanine transaminase peaking at 9740 IU/L. Bilirubin levels rose from 0.25 to 1.30 mg/dl, while ammonia concentrations increased from 19.8 to 85.3 micromol/L. The researchers recorded a marked progression in coagulopathy, evidenced by prothrombin times extending from 8.7 to 46 seconds. Observations revealed increased lability and elevations in intracranial pressures across all subjects. Two of the six animals experienced severe neurological obtundation associated with intracranial pressures exceeding 50 mmHg. Histological examination confirmed massive hepatic necrosis in all post-mortem samples. Microbial growth in blood and ascites suggested possible translocation of intestinal bacteria during the failure process.

Conclusions:

The authors propose that this refined canine model effectively replicates the clinical manifestations of acute liver failure. Synthesis and implications suggest the model provides a robust platform for testing bioartificial liver assist devices. Researchers observed that the model successfully mimics human hepatic necrosis and associated coagulopathy. The team notes that the observed neurological changes and intracranial pressure elevations align with severe clinical presentations. This study indicates that the model is suitable for both qualitative and quantitative assessments of liver support systems. The investigators emphasize that the protocol reduces experimental artifacts seen in earlier canine studies. These findings support the use of this model for future preclinical evaluations of liver-assist technologies. The authors conclude that the model offers a reliable framework for studying the progression of hepatic failure.

The team utilized this data to define the death-equivalent endpoint, which occurred when animals could not maintain systolic blood pressure above 80 mmHg for 20 minutes. This threshold was applied despite the administration of maximal fluids and dopamine infusion at 20 microg/kg/min.

The researchers measured liver enzymes, specifically aspartate transaminase and alanine transaminase, alongside bilirubin, ammonia, and prothrombin time. These markers confirmed progressive liver failure, with aspartate transaminase rising from 26 to 5977 IU/L and alanine transaminase increasing from 32 to 9740 IU/L.

The authors propose that this model is suitable for the qualitative and quantitative evaluation of bioartificial liver assist devices. They suggest that by removing previous experimental artifacts, this framework provides a more accurate representation of clinical liver failure for future preclinical testing.